Sotera Health Company (SHC) Stock Analysis
Temp Headwind edge
Healthcare · Diagnostics & Research
Wait for pullback to $15.06. Weak momentum — blocks BUY_NOW at $15.10. Engine's entry $15.06 (Ma50 Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Leverage penalty (D/E 3.6): -1.5; Negative momentum.
Sotera Health provides mission-critical outsourced sterilization services (Sterigenics gamma/EO/E-beam; Nordion Co-60 supply) and microbiological lab testing/advisory services (Nelson Labs) for medical device and pharmaceutical companies across 62 global facilities. Services are... Read more
Wait for pullback to $15.06. Weak momentum — blocks BUY_NOW at $15.10. Engine's entry $15.06 (Ma50 Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Leverage penalty (D/E 3.6): -1.5; Negative momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Growth is cheap relative to earnings, but the chart hasn't confirmed yet (PEG 0.09, quality 7.8/10, growth 7.5/10). Score 5.9/10, moderate confidence.
Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 78d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Recent Developments — Sotera Health Company
Latest news
- Sotera Health Shifts to Conventional Governance After Sponsors Exit - TipRanks — TipRanks neutral
- Why Broyhill May Be Buying More Sotera Health Shares - The Motley Fool — The Motley Fool positive
- Analysts Offer Insights on Healthcare Companies: Editas Medicine (EDIT), Vertex Pharmaceuticals (VRTX) and Sotera Health — The Globe and Mail neutral
- Wolfe Research lowers Sotera Health stock price target to $19 on valuation - Investing.com — Investing.com negative
- Wolfe Research lowers Sotera Health stock price target to $19 on valuation - Investing.com Canada — Investing.com Canada negative
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 floor-breaker
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait for pullback to $15.06. Weak momentum — blocks BUY_NOW at $15.10. Engine's entry $15.06 (Ma50 Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Leverage penalty (D/E 3.6): -1.5; Negative momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Growth is cheap relative to earnings, but the chart hasn't confirmed yet (PEG 0.09, quality 7.8/10, growth 7.5/10). Target $17.51 (+16.0%), stop $14.11 (−7.0%), Setup A.R:R 2.7:1. Score 5.9/10, moderate confidence.
Take-profit target: $17.51 (+17.2% upside). Target $17.51 (+16.0%), stop $14.11 (−7.0%), Setup A.R:R 2.7:1. Stop-loss: $14.11.
Leverage penalty (D/E 3.6): -1.5; Negative momentum; Value-trap signals (2/5): High leverage (D/E 3.6), Material insider selling (5 sells, 27.41% of cap).
Sotera Health Company trades at a P/E of 37.1 (forward 14.4). TrendMatrix value score: 7.3/10. Verdict: Buy (Wait for Entry).
15 analysts cover SHC with a consensus score of 4.2/5. Average price target: $20.
What does Sotera Health Company do?Sotera Health provides mission-critical outsourced sterilization services (Sterigenics gamma/EO/E-beam; Nordion Co-60...
Sotera Health provides mission-critical outsourced sterilization services (Sterigenics gamma/EO/E-beam; Nordion Co-60 supply) and microbiological lab testing/advisory services (Nelson Labs) for medical device and pharmaceutical companies across 62 global facilities. Services are a regulatory requirement for customers, generating multi-year contract revenue; over 40 of the top 50 medical device companies are served. The company faces ongoing EO emissions tort litigation in multiple states.